Dr. Ping Li

Partner

Munich + 49.89.20.60.42.200

Dr. Ping Li is a European and German patent attorney. Ping has extensive experience in representing international clients before the European Patent Office (EPO), the Unified Patent Court (UPC), the German Federal Patent Court, and German district courts in patent grant, opposition, revocation, and infringement proceedings. Her work covers all aspects of patent prosecution, including drafting, examination, opposition, and appeal proceedings at the EPO. She has worked on numerous invalidity and infringement matters and is experienced in conducting IP due diligence and freedom-to-operate analyses, as well as providing patent validity opinions and advice on supplementary protection certificates (SPCs). Ping represents international clients across the United States, Europe, and Asia in all fields of technology, including biotechnology; life science; lithium-ion battery technology; organic, inorganic, and polymer chemistry; materials chemistry; renewable energy; biofuel production; nanotechnology, adhesive, and paper technology; as well as computer-implemented inventions.

Ping is a synthetic and biophysical chemist by training, with technical experience spanning various areas of chemistry, including organic and inorganic synthesis, NMR (nuclear magnetic resonance) spectroscopy, mass spectrometry, electron microscopy, and radioactive labelling. Her doctoral research at the Max Planck Institute for Biophysical Chemistry in Göttingen led to several peer-reviewed publications, including a first-author publication in the journal Science in 2007. Drawing on her extensive scientific background, Ping brings a deep understanding of inventions across a wide range of technological fields.

Ping is a member of the Institute of Professional Representatives before the European Patent Office (epi), the German Patent Bar Association, the International Federation of Intellectual Property Attorneys, and the German Association for the Protection of Intellectual Property (GRUR).

Experience

  • Sunovion establishes global patent portfolio for small molecule drugs for certain CNS disorders and painJones Day assists Sunovion Pharmaceuticals Inc. in the establishment of a global patent portfolio related to small molecule drugs for the treatment of certain CNS disorders and pain.
  • Idenix establishes patent portfolio related to nucleoside analog antiviral drugsJones Day represents Idenix Pharmaceuticals, Inc. in the management and development of a patent portfolio related to nucleoside analog antiviral drugs.
  • Leading manufacturer of low ignition proclivity papers engages in European oppositionsJones Day represents a leading paper manufacturer before the European Patent Office. 
  • Stopaq asserts in Germany several patents against competitor involving self-healing, anti-corrosion preparations for use on oil and gas pipelinesJones Day is advising Stopaq B.V., a Netherlands-based manufacturer of corrosion protective coatings and sealants, in a multi-patent litigation against a major competitor.
  • Additional Speaking Engagements

    • December 13, 2021
      Women in IP Speaker Series: Artificial Intelligence in the Biopharma Lifecycle: U.S. and EU IP Considerations
    • June 6, 2019
      Successful claim strategies for inventions arising from product development and emerging technologies: US v. EP, AbbVie IP Day 2019
    • September 16, 2015
      Opposition Proceedings at the EPO Webinar